6.33
-0.15(-2.31%)
Currency In USD
| Previous Close | 6.48 |
| Open | 6.45 |
| Day High | 6.48 |
| Day Low | 6.29 |
| 52-Week High | 9.36 |
| 52-Week Low | 5.79 |
| Volume | 1.1M |
| Average Volume | 879,052 |
| Market Cap | 937.49M |
| PE | 24.35 |
| EPS | 0.26 |
| Moving Average 50 Days | 7.05 |
| Moving Average 200 Days | 6.91 |
| Change | -0.15 |
If you invested $1000 in MiMedx Group, Inc. (MDXG) 10 years ago, it would be worth $711.24 as of January 06, 2026 at a share price of $6.33. Whereas If you bought $1000 worth of MiMedx Group, Inc. (MDXG) shares 5 years ago, it would be worth $677.73 as of January 06, 2026 at a share price of $6.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
GlobeNewswire Inc.
Dec 22, 2025 2:43 PM GMT
Company Continues to Broaden Leading Wound Product OfferingMARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
GlobeNewswire Inc.
Dec 19, 2025 2:00 PM GMT
Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repairMARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “C
MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Pro